Kathy Meade has posted this to a prostate cancer support board: I got the note below from VPCC board member Dr. Charles “Snuffy” Myers. Please share with anyone who you think may be interested. Kathy March 11, 2008 Phase II Study: Treatment of Slow-Growing Recurrent Prostate Cancer with Vitamin D3 Dear Kathy: We are initiating [...]
News Flash- Specter-Harkin Amendment Passed
Senators Arlen Specter (R-PA) and Tom Harkin (D-IA) today offered an amendment on the Senate floor to increase NIH funding by an additional $2.1 Billion. The increased funding in the FY09 Congressional Budget Resolution will establish a blueprint for the Senate to dramatically increase funding for cancer research and programs during the appropriations process later [...]
A Little Ray of Sunshine on the Dendreon (Provenge) Front
Yesterday, Dendreon Corp (DNDN) announced that the FDA has agreed to allow them to amend the trial design of its Provenge cancer vaccine. The change in the design will accelerate the expected timing of the final study results by about one year. According to Dendreon, the interim results of the impact study are still expected [...]
Your Action Is Needed Now
Last year 1.5 million Americans were diagnosed with cancer. Every year 560,000 Americans will die from the disease. Over the past five years federal funding has been flat for cancer research. The effect of flat funding has been devastating. The rate of medical inflation far outstrips the rate in the general economy. This means that [...]
ADT1 Monotherapy Causes Many Less Side Effects
Androgen blockades come in many different configurations. One of these configurations known as monotherapy, or ADT1, involves using only the drug Bicalutamide (Casodex). The most common androgen blockade (ADT2) involves using Bicalutamide along with an agonadotropin releasing hormone (GnRH) agonists (i.e. Lupron and Leuprolide). Some men also add a third drug (ADT3), Adovart or Proscar. [...]